노바백스 phase 3

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

https://www.nejm.org/doi/full/10.1056/NEJMoa2107659

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine | NEJM

 

A total of 15,187 participants underwent randomization, and 14,039 were included in the per-protocol efficacy population. Of the participants, 27.9% were 65 years of age or older, and 44.6% had coexisting illnesses. Infections were reported in 10 participants in the vaccine group and in 96 in the placebo group, with a symptom onset of at least 7 days after the second injection, for a vaccine efficacy of 89.7% (95% confidence interval [CI], 80.2 to 94.6). No hospitalizations or deaths were reported among the 10 cases in the vaccine group. Five cases of severe infection were reported, all of which were in the placebo group. A post hoc analysis showed an efficacy of 86.3% (95% CI, 71.3 to 93.5) against the B.1.1.7 (or alpha) variant and 96.4% (95% CI, 73.8 to 99.5) against non-B.1.1.7 variants. Reactogenicity was generally mild and transient. The incidence of serious adverse events was low and similar in the two groups.

 

노바백스 2회 접종 자 - alpha 변이에 대해서도 86.3% 정도, 최대 96.4% 의 효용을 보였다. 

 

치명상에 이르는 부작용은 보고되지 않음. 

 

무기력증, 근육통 정도의 부작용은 있는 것으로 보임.